Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 9(7): e102033, 2014.
Article in English | MEDLINE | ID: mdl-25025687

ABSTRACT

X-linked severe combined immunodeficiency (XSCID) is caused by a genetic mutation within the common gamma chain (γc), an essential component of the cytokine receptors for interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21. XSCID patients are most commonly treated with bone marrow transplants (BMT) to restore systemic immune function. However, BMT-XSCID humans and dogs remain at an increased risk for development of cutaneous papillomavirus (PV) infections and their associated neoplasms, most typically cutaneous papillomas. Since basal keratinocytes are the target cell for the initial PV infection, we wanted to determine if canine XSCID keratinocytes have a diminished antiviral cytokine response to poly(dA:dT) and canine papillomavirus-2 (CPV-2) upon initial infection. We performed quantitative RT-PCR for antiviral cytokines and downstream interferon stimulated genes (ISG) on poly(dA:dT) stimulated and CPV-2 infected monolayer keratinocyte cultures derived from XSCID and normal control dogs. We found that XSCID keratinocytes responded similarly to poly(dA:dT) as normal keratinocytes by upregulating antiviral cytokines and ISGs. CPV-2 infection of both XSCID and normal keratinocytes did not result in upregulation of antiviral cytokines or ISGs at 2, 4, or 6 days post infection. These data suggest that the antiviral response to initial PV infection of basal keratinocytes is similar between XSCID and normal patients, and is not the likely source for the remaining immunodeficiency in XSCID patients.


Subject(s)
Keratinocytes/drug effects , Keratinocytes/metabolism , Papillomavirus Infections/etiology , Poly dA-dT/pharmacology , X-Linked Combined Immunodeficiency Diseases/immunology , Animals , Base Sequence , Bone Marrow Transplantation , Cytokines/genetics , Cytokines/metabolism , Disease Models, Animal , Dogs , Female , Gene Expression , Gene Expression Regulation/drug effects , Interferon Regulatory Factors/genetics , Interferon Regulatory Factors/metabolism , Interleukin Receptor Common gamma Subunit/chemistry , Interleukin Receptor Common gamma Subunit/genetics , Keratinocytes/virology , Molecular Sequence Data , Mutation , Papillomaviridae , Papillomavirus Infections/drug therapy , Poly dA-dT/administration & dosage , Primary Cell Culture , RNA, Messenger/genetics , X-Linked Combined Immunodeficiency Diseases/complications , X-Linked Combined Immunodeficiency Diseases/genetics , X-Linked Combined Immunodeficiency Diseases/therapy
2.
Nat Chem Biol ; 9(4): 250-6, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23416331

ABSTRACT

Targeted delivery of antigens to dendritic cells (DCs) is a promising vaccination strategy. However, to ensure immunity, the approach depends on coadministration of an adjuvant. Here we ask whether targeting of both adjuvant and antigen to DCs is sufficient to induce immunity. Using a protein ligation method, we develop a general approach for linking the immune stimulant, poly dA:dT (pdA:dT), to a monoclonal antibody (mAb) specific for DEC205 (DEC). We show that DEC-specific mAbs deliver pdA:dT to DCs for the efficient production of type I interferon in human monocyte-derived DCs and in mice. Notably, adaptive T-cell immunity is elicited when mAbs specific for DEC-pdA:dT are used as the activation stimuli and are administered together with a DC-targeted antigen. Collectively, our studies indicate that DCs can integrate innate and adaptive immunity in vivo and suggest that dual delivery of antigen and adjuvant to DCs might be an efficient approach to vaccine development.


Subject(s)
Adaptive Immunity/drug effects , Antibodies, Monoclonal/immunology , Antigens, CD/immunology , Antigens/immunology , Dendritic Cells/drug effects , Immunity, Innate/drug effects , Immunoconjugates/immunology , Lectins, C-Type/immunology , Poly dA-dT/immunology , Receptors, Cell Surface/immunology , Adjuvants, Immunologic/administration & dosage , Adjuvants, Immunologic/chemistry , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/chemistry , Antigens/administration & dosage , Antigens/chemistry , Antigens, CD/administration & dosage , Antigens, CD/chemistry , Dendritic Cells/immunology , Drug Delivery Systems , Genetic Vectors , Humans , Immunoconjugates/administration & dosage , Immunoconjugates/chemistry , Interferon Type I/biosynthesis , Interferon Type I/immunology , Lectins, C-Type/administration & dosage , Lectins, C-Type/chemistry , Mice , Mice, Inbred C57BL , Minor Histocompatibility Antigens , Plasmids , Poly dA-dT/administration & dosage , Poly dA-dT/chemistry , Receptors, Cell Surface/administration & dosage , Receptors, Cell Surface/chemistry
3.
Cancer Res ; 70(13): 5293-304, 2010 Jul 01.
Article in English | MEDLINE | ID: mdl-20551064

ABSTRACT

Most malignant cells are poorly immunogenic and fail to elicit an effective antitumor immune response. In contrast, viral infections of cells are promptly detected and eliminated by the immune system. Viral recognition critically hinges on cytosolic nucleic acid receptors that include the proinflammatory RNA helicase retinoic acid-inducible gene-I (RIG-I). Here, we show that targeted delivery of RIG-I agonists induced ovarian cancer cells to upregulate HLA class I and to secrete the proinflammatory cytokines CXCL10, CCL5, interleukin-6, tumor necrosis factor-alpha, and IFN-beta. Ovarian cancer cells stimulated via RIG-I became apoptotic and were readily phagocytosed by monocytes and monocyte-derived dendritic cells, which in turn upregulated HLA class I/II and costimulatory molecules and released CXCL10 and IFN-alpha. Our findings offer proof of principle that mimicking viral infection in ovarian cancer cells triggers an immunogenic form of tumor cell apoptosis that may enhance immunotherapy of ovarian cancer.


Subject(s)
DEAD-box RNA Helicases/metabolism , Ovarian Neoplasms/immunology , Ovarian Neoplasms/therapy , Apoptosis/drug effects , Apoptosis/immunology , Ascites/immunology , Ascites/pathology , Cell Line, Tumor , Cytokines/biosynthesis , Cytokines/genetics , Cytokines/immunology , DEAD Box Protein 58 , DEAD-box RNA Helicases/genetics , DEAD-box RNA Helicases/immunology , Dendritic Cells/immunology , Enzyme Activation , Female , Histocompatibility Antigens Class I/biosynthesis , Histocompatibility Antigens Class I/genetics , Histocompatibility Antigens Class I/immunology , Humans , Ligands , Monocytes/immunology , Ovarian Neoplasms/enzymology , Ovarian Neoplasms/genetics , Poly dA-dT/administration & dosage , RNA, Double-Stranded/administration & dosage , Receptors, Immunologic
4.
Int J Biochem ; 15(10): 1241-8, 1983.
Article in English | MEDLINE | ID: mdl-6313445

ABSTRACT

The ATP-synthesis of the nuclear nucleoside-nucleotide phosphotransferase C was stimulated by progesterone alone and in combination with poly d(A-T) at 10(-10)-10(-9) M, by estradiol/poly d(A-T) at 5-10(-9) M, by cortisol alone and in combination with poly d(A-T) at 10(-9)-10(-8) M and by poly d(A-T) alone. No effect was observed using poly d(C-G). Using increasing adenosine/dTTP as substrates, cortisol, progesterone, estradiol/poly d(A-T) and poly d(A-T) alone caused positive cooperativity of the substrate saturation curves of the allosteric enzyme C by lowering the apparent Ks 0.5-values and by altering Vmax. The dTTP-synthesis of enzyme C was stimulated by both poly d(A-T) and poly d(C-G) alone and in combination with low estradiol (up to 10(-10) M)-and with higher progesterone concentrations (10(-8)-10(-7) M), whereas cortisol inhibited at higher concentrations completely. Using increasing thymidine/ATP as substrates progesterone and estradiol, also in combination with poly d(A-T) were positive effectors of the substrate saturation curves of enzyme C. By this, the apparent Ks 0.5-values or Vmax were changed. Cortisol could be shown to be a negative effector.


Subject(s)
Estradiol/administration & dosage , Hydrocortisone/administration & dosage , Liver Neoplasms, Experimental/enzymology , Phosphotransferases/metabolism , Poly dA-dT/administration & dosage , Polydeoxyribonucleotides/administration & dosage , Progesterone/administration & dosage , Adenosine/metabolism , Allosteric Regulation/drug effects , Animals , Cell Nucleus/enzymology , Dose-Response Relationship, Drug , Kinetics , Male , Rats , Thymidine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...